Claudin-18.2

Claudin-18.2

Claudin-18.2 Molekülinformation

Molecule Name
Claudin-18 splice variant 2
Molekülalias
Claudin-18.2,CLDN18,Claudin-18
Drug Development Progress
Anzahl der klinischen Arzneimittel85
Anzahl der inverkehr gebrachten Arzneimittel1
Höchste Forschungs- und EntwicklungsphaseApproved
Target-Alias
UNQ778/PRO1572,CLDN18,Claudin 18,Surfactant Associated Protein J,Surfactant, Pulmonary Associated Protein J,Surfactant Associated 5,Claudin-18,SFTA5,SFTPJ,Claudin 18.2,CLDN18.2
Molekülhintergrund
Claudins (CLDNs) are a family of proteins that form tight junctions and maintain the polarity of epithelial and endothelial cells. CLDN18 is specifically expressed in the stomach and lung. Of the two CLDN18 isoform transcripts produced by alternative splicing, CLDN18.2 is a highly selective gastric lineage marker that determines the gastric phenotype in a neoplastic condition, whereas CLDN18.1 is lung specific. CLDN18.2 is a highly selective gastric lineage antigen expressed exclusively on short-lived differentiated gastric epithelial cells where it has only limited accessibility to antibody drugs.14,15 CLDN18.2 is maintained during the course of malignant transformation and thus frequently displayed on the surface of human gastric cancer cells.

Claudin-18.2 Produktliste

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Antikörperprojekt-Handelsplattform

ProjektnameProjektphaseMolekültypMolekülquelleKrankheitsgebietIndikationen
CLDN18.2 CAR-T - 01PhaseICARNanobodySolid TumorAdvanced refractory gastrointestinal tumors
CLDN18.2 VHH - 01LeadMonoclonalNanobodySolid TumorGastric Cancer,Pancreatic cancer
Projektphase
PhaseI
Molekültyp
CAR
Molekülquelle
Nanobody
Krankheitsgebiet
Solid Tumor
Indikationen
Advanced refractory gastrointestinal tumors
Projektphase
Lead
Molekültyp
Monoclonal
Molekülquelle
Nanobody
Krankheitsgebiet
Solid Tumor
Indikationen
Gastric Cancer,Pancreatic cancer

Lizenzierungszusammenarbeit

ProjektnameArzneimitteltypTherapiegebietIndikationenStufeRechtsgebiet
Claudin18.2×CD8+ T bsAbBispecific antibodyOncology/CancerGastric cancer,Pancreatic cancer,OophoromaINDGlobal
CLDN 18.2 CAR-TCell therapyOncology/CancerGastric Cancer,Pancreatic CancerINDGlobal
Claudin18.2 mAbMonospecific antibodyOncology/CancerGastric cancerPhase IGlobal
Arzneimitteltyp
Bispecific antibody
Therapiegebiet
Oncology/Cancer
Indikationen
Gastric cancer,Pancreatic cancer,Oophoroma
Stufe
IND
Rechtsgebiet
Global
Projektname
CLDN 18.2 CAR-T
Arzneimitteltyp
Cell therapy
Therapiegebiet
Oncology/Cancer
Indikationen
Gastric Cancer,Pancreatic Cancer
Stufe
IND
Rechtsgebiet
Global
Projektname
Claudin18.2 mAb
Arzneimitteltyp
Monospecific antibody
Therapiegebiet
Oncology/Cancer
Indikationen
Gastric cancer
Stufe
Phase I
Rechtsgebiet
Global